Membranoprolferative glomerulonephritis - Mechanisms and treatment

Contributions to Nephrology

Volumn 181, Issue , 2013, Pages 163-174

  Appel, Gerald B ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3;

ARTICLE; COMPLEMENT ALTERNATIVE PATHWAY; GLOMERULUS; HUMAN; IMMUNOLOGY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PATHOLOGY;

COMPLEMENT C3; COMPLEMENT PATHWAY, ALTERNATIVE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; KIDNEY GLOMERULUS;

EID: 84879096686     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000348635     Document Type: Article

References (32)

1. Sethi S, Fervenza FC: Membranoproliferative glomerulonephritis-a new look at an old entity. N Engl J Med 2012; 366:1119-1131.
2. Sethi S, Fervenza FC: Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol 2011; 31:341-348.
3. Swaminathan S, Leung N, Lager DJ, et al: Changing incidence of glomerular disease in Olmstead County, Minnesota: a 30-year renal biopsy study. Clin J Am Soc Nephrol 2006; 1: 483-487.
4. Braden GL, Mulhern JG, O'Shea MH, et al: Changing incidence of glomerular disease in adults. Am J Kidney Dis 2000; 35:878-883. (Pubitemid 30238200)
5. Maisonneuve P, Agadoa L, Gellert R, et al: Distribution of primary renal diseases leading to ESRF in the United States, Europe, and Australia/New Zealand. Am J Kidney Dis 2000: 35:157-165.
6. Levy M, Gubler MC, Sich M, et al: Immuno-pathology of membranoproliferative glomer-ulonephritis with subendothelial deposits (type I MPGN). Clin Immunol Immuno-pathol 1978; 10:477-492. (Pubitemid 9010720)
7. Habib R, Gubler MC, Loirat C, et al: Dense deposit disease: a variant of membranoprolif-erative glomerulonephritis. Kidney Int 1975; 7:204-215.
8. Fakhouri F, Fremeaux-Bacchi V, Noel L-H, et al: C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010; 6:494-499.
9. Bomback AS, Appel GB: Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol 2012; 8:634-642.
10. Rennke HG: Secondary membranoprolifera-tive glomerulonephritis. Kidney Int 1995; 47: 643-656.
11. Strife CF, McEnery PT, McAdams AJ, West CD: Membranoproliferative glomerulone-phritis with disruption of the glomerular basement membrane. Clin Nephrol 1977; 7: 65-72. (Pubitemid 8060072)
12. Tarshih P, Bernstein J, Tobin JN, Edelman CN Jr: Treatment of mesangiocapillary glo-merulonephritis with alternate-day predni-sone-a report of the International Study of Kidney Disease in Children. Pediatr Nephrol 1992; 6:123-130.
13. Johnson RJ, Gretch DR, Yamabe H, et al: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328:465-470. (Pubitemid 23056436)
14. Rocatello D, Fornasierri A, Gianchino O, et al: Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephrtiis. Am J Kidney Dis 2007; 49:69-82.
15. Sethi S, Nester CM, Smith RJ: Membranopro-liferative glomerulonephritis and C3 glomer-ulopathy: resolving the confusion. Kidney Int 2012; 81:434-441.
16. D'Agati VD, Bomback AS: C3 Glomerulopa-thy: what's in a name? Kidney Int 2012; 82: 379-381.
17. Appel GB, Cook HT, Hageman G, et al: Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 2005; 16:1392-1403. (Pubitemid 41716523)
18. Nasr SH, Valeri AM, Appel GB, et al: Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 2009; 4:22-32.
19. Sethi S, Gamez JD, Vrana JA, et al: Glomeruli of DDD contain components of the alternative and terminal complement pathway. Kidney Int 2009; 75:852-960.
20. Walker PD, Ferrario F, Joh K, Bonsib SM: Dense deposit disease is not a membranopro-liferative glomerulonephritis. Mod Pathol 2007; 20:605-616. (Pubitemid 46788867)
21. Servais A, Fremeaux-Bacchi V, Lequintrec M, et al: Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007; 44: 193-199. (Pubitemid 46580528)
22. Servais A, Noel L-H, Roumenina LT, et al: Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82:454-463.
23. Sethi S, Fervenza F, Zhang Y, et al: C3 glo-merulonephritis: clinicopathological findings, complement abnormalities, glomerular pro-teomic profile, treatment and follow-up. Kidney Int 2012; 82:465-473.
24. Herlitz LC, Bomback AS, Markowitz GS, et al: Renal biopsy findings after eculizumab treatment in dense deposit disease and C3 glomerulonephritis. J Am Soc Nephrol 2012; 23:1229-1237.
25. Pickering M, Cook HT: Complement and glomerular disease: new insights. Curr Opin Nephrol Hypertens 2011; 20:271-277.
26. Gale DP, de Jorge EG, Cook HT, et al: Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010; 376:794-801.
27. Habbig S, Mihatsch MJ, Heinen S, et al: C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int 2009; 75:1230-1234.
28. Zhang Y, Meyer NC, Wang K, et al: Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol 2012; 7:265-274.
29. Bomback AS, Smith RJ, Barile GR, et al: Ecu-lizumab for dense deposit disease and C3 glo-merulonephritis. Clin J Am Soc Nephrol 2012; 7:748-756.
30. Noris M, Remuzzi G: Atypical hemolytic ure-mic syndrome. N Engl J Med 2009; 361:1676-1687.
31. Maga TK, Nishimura CJ, Weaver AE, et al: Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 2010; 31:E1445-E1460.
32. KDIGO Clinical Practice Guidelines for Glo-merulonephritis. Idiopathic MPGN. Kidney Int 2012;(suppl 2):198-199.